Harbour BioMed has announced the advancement of its global strategic collaboration with AstraZeneca, expanding the partnership first established in March 2025. The alliance focuses on discovering and developing next-generation biotherapeutics, including antibody-drug conjugates and T-cell engagers, by combining the scientific strengths of both companies.

As part of the updated agreement, AstraZeneca will continue to nominate discovery programmes to Harbour BioMed annually over the next four years and will retain the option to license these programmes for further development. Harbour BioMed will be eligible for option and exercise fees, development and commercial milestone payments, and tiered royalties on future net sales. The financial structure remains consistent with the original terms set in 2025.

Dr. Jingsong Wang, founder, chairman and CEO of Harbour BioMed, said the expanded collaboration reflects a trusted partnership built over multiple programmes since 2022 and strengthens efforts to advance innovative oncology therapies.

Harbour BioMed continues to develop a differentiated pipeline in immunology and oncology through internal research, global collaborations, and selective acquisitions.